



World-leading expertise in Gene and Cell Therapy

Jefferies Healthcare Conference
New York, June 2015

Disclaimer

The information contained in this presentation is being supplied and communicated to you on a confidential basis solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. For the purpose of this disclaimer, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings or any presentation to which this document relates.


Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford BioMedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares in the Company (the “Securities”). The Securities have not been registered under the US Securities Act of 1933, as amended (the “Securities Act”), or qualified for sale under the law of any state or other jurisdiction of the United States of America and may not be offered or sold in the United States of America except pursuant to such registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Neither the United States Securities and Exchange Commission nor any securities regulatory body of any state or other jurisdiction of the United States of America, nor any securities regulatory body of any other country or political subdivision thereof, has approved or disapproved of this presentation or the securities discussed herein or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is unlawful.

This presentation is being communicated only to U.S. persons that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.

By participating in this presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer.




A leading gene and cell therapy company


- Spun out of Oxford University in 1996
- London Stock Exchange (Ticker OXB.L)
- Market capitalisation - \$405m (May 25, 2015)
- \$22m cash at December 31, 2014, plus \$50m loan facility

In vivo

ProSavin® (Parkinson's disease)




RetinoStat® (Wet AMD)




Ex vivo

Lentivector manufacturing for CTL019




1. Larger therapeutic payloads
2. Permanent modification of dividing cells such as T-cells or stem cells

Potential for “one shot” treatment giving long-term or permanent efficacy



One stop shop

Oxford BioMedica's business model



Product Portfolio

Portfolio of pipeline assets (excluding those already out-licensed)

	Product	Indication	Stage	Next inflection	Est. date
Lentiviral vector TECHNOLOGY					
OPHTHALMOLOGY	RetinoStat®	Wet AMD	Phase I follow up stage (primary end point met)	Phase I CSR	2015
	EncorStat®	Corneal graft rejection	Phase I/II preparation	FPI Phase I/II	2016
	Glaucoma-GT	Chronic glaucoma	Pre-clinical	End pre-clinical	2016
CNS	ProSavin® OXB-102	Parkinson's disease	Phase I/II complete Phase I/II preparation	FPI Phase I/II	2016
	MoNuDin®	Motor neuron disease	Research	End pre-clinical	2015
NEW IDEAS	Investigating several therapy areas where Lenti based vectors have an advantage over AAV due to payload capacity			TBD	TBD
	Exploring possibilities to enter cell therapy field in our own right – e.g. CAR-T 5T4				
5T4 TECHNOLOGY					
ONCOLOGY	TroVax®	Cancer (multiple)	3 x Phase II ongoing	End Phase II	2015/16
	CAR-T 5T4	Cancer (multiple)	Pre-clinical	End pre-clinical	2016

Licences to OXB's IP and products

	Company	Products	Terms	Estimated launch date	Estimated Peak Yr Sales
Lenti based vector					
IP & Know-how	Novartis	CTL019/ Other CAR-T	\$10m upfront Undisclosed royalties	2017	"Multi billion \$"
	GSK	Up to 6 rare orphan diseases	Not disclosed	TBD	\$10m—\$50m per product
Products	Sanofi	StarGen™	Undisclosed development milestones and royalties	2021	\$500m
	Sanofi	UshStat®		2021	\$90m
5T4 Tumour antigen					
IP	Pfizer	5T4 antibody	Undisclosed	2023	>\$300m
IP	ImaginAb	5T4 imaging diagnostic	Undisclosed	2024	\$10m
PrimeBoost					
IP	Bavarian Nordic	PROSTVAC™	Undisclosed	2017	\$60m

Game-changing Novartis contract

- Non-exclusive licence to OXB's IP
- Initial 3 year manufacturing contract for clinical supply for NVS CTL019 programme – potential to extend
- Process development collaboration
- Financial terms include
 - \$14m up front, including an equity investment and IP licence
 - Undisclosed royalties on CTL019 and other CAR-T products
 - Up to \$76m over 3 year manufacturing and process development



Transforming cash flows

Windrush Court Corporate Headquarters & Laboratories



Harrow House
(GMP1/GMP2/GMP3)
Fill & Finish
API manufacturing facility



Yarnton (GMP4)
API manufacturing
facility



- Cash at end 2014 – £14m
- \$50m loan facility secured May 2015
 - \$25m drawn down
 - £3m AMSCI loan repaid and facility terminated
- Capital expenditure across 2015/2016 expected to be in the region of £20m
- Manufacturing and process development revenues set to grow in 2015, reducing underlying operational cash burn

Upcoming potential value driving news flow

- 2015
- Further IP licences/manufacturing/process development contracts
 - RetinoStat[®] decision regarding Phase II indication and development pathway
 - Identification of new product development candidates
 - TroVax[®] Phase II studies – initial results
- 2016
- MoNuDin[®] pre-clinical results
 - FPI OXB-102 clinical programme
 - FPI EncorStat[®] clinical programme
 - StarGen[™]/UshStat[®] development milestones
 - Glaucoma-GT pre-clinical results
 - CAR-T 5T4 pre-clinical results

Plus updates from Novartis on CTL019 programme from time to time

In summary

- Wholly-owned high-value clinical pipeline for value generation
 - Three gene therapy product candidates in Phase I/II development
 - Three investigator-led Phase II TroVax[®] studies
- Out-licensed clinical programmes  
 - Two ophthalmology *in vivo* Phase I/II products licensed to Sanofi
 - Two out-licensed 5T4 antibody technology phase I studies
- Further innovative product development opportunities for value creation
 - Including CAR-T 5T4
- Lentiviral vector IP recognised by Novartis, GSK  
- Significant revenue potential from manufacturing and process development offsets cash burn

Oxford BioMedica plc

Windrush Court
Transport Way
Oxford
OX4 6LT
United Kingdom

www.oxfordbiomedica.co.uk

www.oxbsolutions.co.uk

enquiries@oxfordbiomedica.co.uk

John Dawson, CEO

Tim Watts, CFO

Tel: +44 (0) 1865 783 000